PRTN3 and rheumatoid arthritis: The EULAR guidelines propose the use of a multiplication factor of 1.5 to estimate the cardiovascular risk in RA patients with a disease duration of more than 10 years, with extraarticular manifestations and positive serology for RF or ACPA.